Literature DB >> 8593186

Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein.

R Monaco1, J M Chen, D Chung, P Brandt-Rauf, M R Pincus.   

Abstract

The ras-oncogene-encoded p21 protein becomes oncogenic if amino acid substitutions occur at critical positions in the polypeptide chain. The most commonly found oncogenic forms contain Val in place of Gly 12 or Leu in place of Gln 61. To determine the effects of these substitutions on the three-dimensional structure of the whole p21 protein, we have performed molecular dynamics calculations on each of these three proteins bound to GDP and magnesium ion to compute the average structures of each of the three forms. Comparisons of the computed average structures shows that both oncogenic forms with Val 12 and Leu 61 differ substantially in structure from that of the wild type (containing Gly 12 and Gln 61) in discrete regions: residues 10-16, 32-47, 55-74, 85-89, 100-110, and 119-134. All of these regions occur in exposed loops, and several of them have already been found to be involved in the cellular functioning of the p21 protein. These regions have also previously been identified as the most flexible domains of the wild-type protein and have been bound to be the same ones that differ in conformation between transforming and nontransforming p21 mutant proteins neither of which binds nucleotide. The two oncogenic forms have similar conformations in their carboxyl-terminal domains, but differ in conformation at residues 32-47 and 55-74. The former region is known to be involved in the interaction with at least three downstream effector target proteins. Thus, differences in structure between the two oncogenic proteins may reflect different relative affinities of each oncogenic protein for each of these effector targets. The latter region, 55-74, is known to be a highly mobile segment of the protein. The results strongly suggest that critical oncogenic amino acid substitutions in the p21 protein cause changes in the structures of vital domains of this protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593186     DOI: 10.1007/bf01888140

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  27 in total

1.  ras proteins can induce meiosis in Xenopus oocytes.

Authors:  C Birchmeier; D Broek; M Wigler
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

2.  On the multiple-minima problem in the conformational analysis of polypeptides. II. An electrostatically driven Monte Carlo method--tests on poly(L-alanine).

Authors:  D R Ripoll; H A Scheraga
Journal:  Biopolymers       Date:  1988-08       Impact factor: 2.505

3.  Biological and biochemical properties of human rasH genes mutated at codon 61.

Authors:  C J Der; T Finkel; G M Cooper
Journal:  Cell       Date:  1986-01-17       Impact factor: 41.582

4.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.

Authors:  S J Leevers; H F Paterson; C J Marshall
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

5.  Structural significance of the GTP-binding domain of ras p21 studied by site-directed mutagenesis.

Authors:  D J Clanton; Y Y Lu; D G Blair; T Y Shih
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

6.  Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.

Authors:  P Chardin; J H Camonis; N W Gale; L van Aelst; J Schlessinger; M H Wigler; D Bar-Sagi
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

7.  Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein.

Authors:  D W Stacey; H F Kung
Journal:  Nature       Date:  1984 Aug 9-15       Impact factor: 49.962

8.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

9.  A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes.

Authors:  D L Chung; P Brandt-Rauf; R B Murphy; S Nishimura; Z Yamaizumi; I B Weinstein; M R Pincus
Journal:  Anticancer Res       Date:  1991 Jul-Aug       Impact factor: 2.480

10.  Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis.

Authors:  E F Pai; U Krengel; G A Petsko; R S Goody; W Kabsch; A Wittinghofer
Journal:  EMBO J       Date:  1990-08       Impact factor: 11.598

View more
  5 in total

1.  Comparison of molecular dynamics averaged structures for complexes of normal and oncogenic ras-p21 with SOS nucleotide exchange protein, containing computed conformations for three crystallographically undefined domains, suggests a potential role of these domains in ras signaling.

Authors:  Thomas Duncan; James M Chen; Fred K Friedman; Mark Hyde; Lyndon Chie; Matthew R Pincus
Journal:  Protein J       Date:  2004-04       Impact factor: 2.371

2.  Computed three-dimensional structures for the ras-binding domain of the raf-p74 protein complexed with ras-p21 and with its suppressor protein, rap-1A.

Authors:  J M Chen; S Manolatos; P W Brandt-Rauf; R B Murphy; R Monaco; M R Pincus
Journal:  J Protein Chem       Date:  1996-08

3.  Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: molecular dynamic and immunologic analyses.

Authors:  P W Brandt-Rauf; J M Chen; M J Marion; S J Smith; J C Luo; W Carney; M R Pincus
Journal:  J Protein Chem       Date:  1996-05

4.  Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.

Authors:  Wilbur B Bowne; Josef Michl; Martin H Bluth; Michael E Zenilman; Matthew R Pincus
Journal:  Cancer Ther       Date:  2007

5.  Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.

Authors:  Sara Tomei; Sharon Adams; Lorenzo Uccellini; Davide Bedognetti; Valeria De Giorgi; Narnygerel Erdenebileg; Maria Libera Ascierto; Jennifer Reinboth; Qiuzhen Liu; Generoso Bevilacqua; Ena Wang; Chiara Mazzanti; Francesco M Marincola
Journal:  Med Oncol       Date:  2012-05-22       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.